Teverelix

DB05624InvestigationalSmall molecule

A synthetic decapeptide, water-soluble Gonadotropin-releasing hormone antagonist. It has reached phase II clinical trials.

Mechanism: Teverelix is a GnRH (Gonadotropin releasing hormone) antagonist.
Curator reviewed
Primary indication: Investigated for use/treatment in benign prostatic hyperplasia, endometriosis, and prostate cancer.Curator reviewed
Formula / weight: C₇₄H₁₀₀ClN₁₅O₁₄ · 1459.16 g/mol (avg)
Also known as: Antarelix
Code names: D-23234 · EP-24332 · TZTX-001

Resolves to

Compound

UNIID19V7048JKCAS151272-78-5

Structure

InChIKeyNOENHWMKHNSHGX-IAOPALDYSA-NSMILES

CC(C)C[C@H](NC(=O)[C@@H](CCCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O

Targets

P30968GNRHR

What you can answer from here — as of February 21, 2021

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Teverelix, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account